Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors, promising drugs in treatment of Alzheimer’s disease (not introduced yet), were modified in this way in order to improve blood–brain permeability due to increased lipophilicity [15]. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.